NCT01924793: An overdue trial by Ansun Biopharma, Inc.
This trial is overdue. It was due to report 6 years, 10 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT01924793 |
|---|---|
| Title | An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 31, 2013 |
| Completion date | May 31, 2017 |
| Required reporting date | May 31, 2018, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 2, 2025 |
| Days late | 2498 |